Ali Keshavarzian is a Gastroenterology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1725 W Harrison St
Suite 207
Chicago, IL 606123841
Telephone
312-942-5861Registry record last updated 8 Jul 2007.
Clinical trials
- A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
Sponsor: Rush University Medical Center
- Mitopure™ (Proprietary Urolithin A) Bioavailability in Healthy Adults
Sponsor: Amazentis SA
- Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
Sponsor: Rush University Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
54.2%Proton pump inhibitor10.9%Pantoprazole Sodium55%Omeprazole21%Esomeprazole Magnesium12%Lansoprazole11%Part D<11 patientsAminosalicylate8.6%Mesalamine69%Sulfasalazine31%Part D<11 patients+ 15 more classes in this area
Cancer & immunology
27.7%Interleukin-12 Antagonist11.2%Stelara100%Part D≥16 patientsTNF inhibitor6.2%Humira(Cf) Pen83%Simponi17%Part D<11 patients+ 5 more classes in this area
Blood & clotting
6.6%Salt solutions5.5%Sodium Chloride100%Part D<11 patientsSolutions for parenteral nutrition1.1%Sodium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
13 NIH research awards on record, funded 1987–2026 per NIH RePORTER. The latest:
- The Bidirectional Gut-Microbiota-Brain Axis in Parkinson’s disease: integrating mechanistic biomarkers of disease severity and progression
Rush University Medical Center
FY2026$700,162U01DK140923 - Center for Circadian Rhythms and Alcohol-Induced Tissue Damage
Rush University Medical Center
FY2026$541,661R24AA026801
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”